RxDoctor Payments Data

Colleen Karasinski

Psychiatric/Mental Health · Somers Point, NJNPI 1013171206

Payments from drug & device makers

$4,551in general payments, 2019–2025

Across 182 payments — averaging $25.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Alkermes, Inc.$695
  • AbbVie$580
  • Neurocrine Biosciences, Inc.$551
  • Otsuka America Pharmaceutical, Inc.$420
  • Axsome Therapeutics, Inc.$301
  • plus $452 from 11 others

What the payments were for

  • Food & beverage$4,49299%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,551 in reported general payments places this provider in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$27,043
Medicare patients
40
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate26$43,568
VraylarCariprazine Hcl13$18,398
Aripiprazole88$4,557
Quetiapine Fumarate49$2,197
Duloxetine Hcl64$2,130
Vilazodone Hcl16$1,904
Bupropion XlBupropion Hcl68$1,413
Lamotrigine89$1,149
Escitalopram Oxalate127$1,130
Olanzapine45$1,038
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine58$957
Clonazepam122$945
Venlafaxine Hcl ErVenlafaxine Hcl44$895
Ziprasidone Hcl15$726
Sertraline Hcl89$660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,552$43,56826 claims
AbbVieVraylar$580$18,39813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Somers Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →